Endostar combined with cisplatin inhibits tumor growth and lymphatic metastasis of lewis lung carcinoma xenografts in mice

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 5, 2013, Pages 3079-3083

  Dong, Xiao Peng ^a   Xiao, Tian Hui ^a   Dong, Hong ^a   Jiang, Ning ^a   Zhao, Xiao Gang ^a  

^a THE SECOND HOSPITAL OF SHANDONG UNIVERSITY   (China)

Author keywords

Cisplatin; Endostatin; Lung tumor; Lymphangiogenesis

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; ENDOSTAR PROTEIN; ENDOSTATIN;

ANIMAL; APOPTOSIS; ARTICLE; C57BL MOUSE; CELL PROLIFERATION; DRUG EFFECT; DRUG SCREENING; ENZYME IMMUNOASSAY; FEMALE; HUMAN; LEWIS CARCINOMA; LYMPH NODE METASTASIS; LYMPH VESSEL; METASTASIS; MORTALITY; MOUSE; PATHOLOGY; SURVIVAL RATE; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, LEWIS LUNG; CELL PROLIFERATION; CISPLATIN; ENDOSTATINS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; LYMPHATIC VESSELS; MICE; MICE, INBRED C57BL; SURVIVAL RATE; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84880340012     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.5.3079     Document Type: Article

References (24)

1. Brideau G, Mäkinen MJ, Elamaa H, et al (2007). Endostatin overexpression inhibits lymphangiogenesis and lymph node metastasis in mice. Cancer Res, 67, 11528-35.
2. Boehm T, Folkman J, Browder T, et al (1997). Antiangiogenic therapy of experimental cancer dose not induce acquired drug resistance. Nature, 390, 404-7.
3. Cheng K, Zhao F, Gao F, et al (2012). Factors potentially associated with chemotherapy-induced anemia in patients with solid cancers. Asian Pac J Cancer Prev, 13, 5057-61.
4. Detmar M, Hirakawa S (2002). The formation of lymphatic vessels and its importance in the setting of malignancy. J Exp Med, 196, 713-8.
5. Folkman J (2006). Angiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp Cell Res, 312, 594-607.
6. Fukumoto S, Morifuji M, Katakura Y, et al (2005). Endostatin inhibits lymph node metastasis by a down-regulation of the vascular endothelial growth factor C expression in tumor cells. Clin Exp Metastasis, 22, 31-8.
7. Han Q, Fu Y, Zhou H, et al (2007). Contributions of Zn (II)- binding to the structural stability of endostatin. FEBS Lett, 581, 3027-32.
8. Huang G, Chen L (2010). Recombinant human endostatin improves anti-tumor efficacy of paclitaxel by normalizing tumor vasculature in Lewis lung carcinoma. J Cancer Res Clin Oncol, 136, 1201-11.
9. Klement G, Huang P, Mayer B, et al (2002). Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrugresistant human breast cancer xenografts. Clin Cancer Res, 8, 221-32.
10. Krishnan J, Kirkin V, Steffen A, et al (2003). Differential in vivo and in vitro expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in tumors and its relationship to lymphatic metastasis in immunocompetent rats. Cancer Res, 63, 713-22.
11. Ling Y, Yang Y, Lu N, et al (2007). Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem Biophys Res Commun, 361, 79-84.
12. Liu ZY, Qiu HO, Yuan XJ, et al (2012). Suppression of lymphangiogenesis in human lymphatic endothelial cells by simultaneously blocking VEGF-C and VEGF-D/VEGFR-3 with norcantharidin. Int J Oncol, 41, 1762-72.
13. Makinen T, Jussila L, Veikkola T (2001). Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med, 7, 199-205.
14. Ma X, Yao Y, Yuan D, et al (2012). Recombinant human endostatin endostar suppresses angiogenesis and lymphangiogenesis of malignant pleural effusion in mice. PLoS One, 7, e53449.
15. Miller KD, Sweeney CJ, Sledge GW (2001). Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol, 19, 1195-206.
16. Nyberg P, Xie L, Kalluri R (2005). Endogenous inhibitors of angiogenesis. Cancer Res, 65, 3967-79.
17. O'Reilly MS, Boehm T, Shing Y(1997). Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 88, 277-85.
18. Rong B, Yang S, Li W, et al (2012). Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer. World J Surg Oncol, 24, 170.
19. Shao XJ, Xie FM(2005). Influence of angiogenesis inhibitors, endostatin and PF-4, on lymphangiogenesis. Lymphology, 38, 1-8.
20. Shimizu K, Kubo H, Yamaguchi K (2004). Suppression of VEGFR-3 signaling inhibits lymph node metastasis in gastric cancer. Cancer Sci, 5, 328-33.
21. Sun Y, Wang J, Liu Y, et al (2005). Results of phase III trial of rhendostatin (YH-16) in advanced non-small cell lung cancer (NSCLC) patients. Annual ASCO Meeting, May in FL, USA.
22. Wakisaka N, Hirota K, Kondo S, et al (2012). Induction of lymphangiogenesis through vascular endothelial growth factor-C/vascular endothelial growth factor receptor 3 axis and its correlation with lymph node metastasis in nasopharyngeal carcinoma. Oral Oncol, 48, 703-8.
23. Wang Z, Chen Y, Li X, et al (2012). Expression of VEGF-C/VEGFR-3 in human laryngeal squamous cell carcinomas and its significance for lymphatic metastasis. Asian Pac J Cancer Prev, 13, 27-31.
24. Yancopoulos GD, Davis S, Gale NW(2000). Vascular-speciflc growth factors and blood vessel formation. Nature, 407, 242-8.